Home › NCT07244419
Prevention of Graft Rejection in Hematopoietic Stem Cell Transplant (HSCT) Recipients
Emapalumab for the Prevention of Graft Rejection in Hematopoietic Stem Cell Transplant (HSCT) Recipients
Who can join
All ages · All sexes
Full eligibility criteria
Inclusion Criteria: * All patients undergoing allogeneic HSCT at our institution will be evaluated for graft rejection risk factors. Patients deemed high risk for graft rejection will have 2 or more of the following: mismatched or haploidentical donor, ex vivo t-cell depleted graft, prior history of graft rejection. Exclusion Criteria: * Known hypersensitivity to any constituent of the study medication.
About the study
The investigators hypothesize that graft rejection after hematopoietic stem cell transplant (HSCT) is primarily driven by interferon gamma, and prophylactic interferon gamma inhibition in high-risk patients will prevent graft rejection. Additionally, knowledge of emapalumab PK/PD and in vitro mechanistic effects of emapalumab in this novel setting will guide optimization of dosing regimens and treatment approaches in future studies.
What is being tested
- Emapalumab 3 mg/kg (drug)
- Emapalumab 10 mg/kg (drug)
Sponsor: Children's Hospital Medical Center, Cincinnati · Participants: 20 · Started: Jan 7, 2026
Contact the study team
- Jessica Anderson, BSN, RN, CCRC · Phone: 513-636-4200
- Manisha Pathak, MS · Phone: 513-636-4200
Official record on ClinicalTrials.gov — NCT07244419
Locations in the U.S.
| Ohio | Cincinnati Children's Hospital Medical Center, Cincinnati |
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.